ONTAK Side Effects

6044006-8 | Blood Creatine Phosphokinase Increased, Tumour Lysis Syndrome
on Jan 16, 2009 Female patient from UNITED STATES , weighting 134.5 lb, was diagnosed with t-cell lymphoma, hypercholesterolaemia, hypertension and was treated with Ontak (View Usage). Patient experienced the following unwanted or unexpected effects: blood creatine phosphokinase increased, tumour lysis syndrome. Ontak dosage: . During the same period patient was treated with VINCRISTINE SULFATE (View Vincristine Sulfate Review and Vincristine Sulfate Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), CYTOXAN (View Cytoxan Review and Cytoxan Label ), PREDNISONE (View Prednisone Review and Prednisone Label ), LIPITOR (View Lipitor Review and Lipitor Label ), LISINOPRIL (View Lisinopril Review and Lisinopril Label ), HYDROCHLOROTHIAZIDE (View Hydrochlorothiazide Review and Hydrochlorothiazide Label ), NEULASTA (View Neulasta Review and Neulasta Label ).

5999774-8 | Infection
Patient was taking Ontak (View Usage). Patient had the following side effects: infection (What is infection?) on Dec 04, 2008 from UNITED STATES Additional patient health information: Female patient , weighting 134.5 lb, . Ontak dosage: . During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), PREDNISONE TAB (View Prednisone Tab Review and Prednisone Tab Label ), PANTOPRAZOLE SODIUM (View Pantoprazole Sodium Review and Pantoprazole Sodium Label ), VALACYCLOVIR HYDROCHLORIDE (View Valacyclovir Hydrochloride Review and Valacyclovir Hydrochloride Label ). Patient was hospitalized and became disabled.

5990475-9 | Lymphopenia
Adverse event was reported on Dec 04, 2008 by a Female patient taking Ontak (View Usage) (Dosage: ) . Location: UNITED STATES , weighting 134.5 lb, After Ontak was administered, patient had the following side effects: lymphopenia. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), DOXORUBICIN (View Doxorubicin Review and Doxorubicin Label ), LORAZEPAM (View Lorazepam Review and Lorazepam Label ), OXYCODONE HCL (View Oxycodone Hcl Review and Oxycodone Hcl Label ), PREDNISONE TAB (View Prednisone Tab Review and Prednisone Tab Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ). Patient was hospitalized.

5989416-X | Infection
on Dec 04, 2008 Female patient from UNITED STATES , weighting 134.5 lb, was treated with Ontak (View Usage). Patient experienced the following unwanted or unexpected effects: infection (What is infection?). Ontak dosage: . During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), DOXORUBICIN (View Doxorubicin Review and Doxorubicin Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), PREDNISONE TAB (View Prednisone Tab Review and Prednisone Tab Label ), NEULASTA (View Neulasta Review and Neulasta Label ), LORAZEPAM (View Lorazepam Review and Lorazepam Label ), OXYCODONE HCL (View Oxycodone Hcl Review and Oxycodone Hcl Label ), VALACYCLOVIR HYDROCHLORIDE (View Valacyclovir Hydrochloride Review and Valacyclovir Hydrochloride Label ). Patient was hospitalized.


5940259-2 | Acute Myocardial Infarction, Cardiac Failure Congestive, Coronary Artery Occlusion, Myocardial Ischaemia, Unresponsive To Stimuli
on Oct 31, 2008 Male patient from UNITED STATES , weighting 246.5 lb, was treated with Ontak (View Usage). Patient had the following side effects: acute myocardial infarction, cardiac failure congestive, coronary artery occlusion, myocardial ischaemia, unresponsive to stimuli. Ontak dosage: 4003.2 Mcg. During the same period patient was treated with RITUXIMAB (MOAB C2B8 ANTI CD20 CHIMERIC) (900 Mg) (View Rituximab (moab C2b8 Anti Cd20 Chimeric) Review and Rituximab (moab C2b8 Anti Cd20 Chimeric) Label ). Patient was hospitalized.

5924832-3 | Acute Myocardial Infarction, Cardiac Failure Congestive, Myocardial Ischaemia, Sedation, Stent Occlusion, Unresponsive To Stimuli
Patient was taking Ontak (View Usage). After Ontak was administered, patient had the following side effects: acute myocardial infarction, cardiac failure congestive, myocardial ischaemia, sedation, stent occlusion, unresponsive to stimuli on Oct 17, 2008 from UNITED STATES Additional patient health information: Male patient , weighting 246.5 lb, . Ontak dosage: 4003.2 Mcg. During the same period patient was treated with RITUXIMAB (MOAB C2B8 ANTI CD20, CHIMERIC) (900 Mg) (View Rituximab (moab C2b8 Anti Cd20, Chimeric) Review and Rituximab (moab C2b8 Anti Cd20, Chimeric) Label ). Patient was hospitalized.

5920554-3 | Cardiac Failure Chronic, Myocardial Infarction
Adverse event was reported on Oct 15, 2008 by a Male patient taking Ontak (View Usage) (Dosage: 4003.2 Mcg) . Location: UNITED STATES , weighting 246.5 lb, Patient experienced the following unwanted or unexpected effects: cardiac failure chronic, myocardial infarction. During the same period patient was treated with RITUXIMAB (MOAB C2B8 ANTI CD20, CHIMERIC) (900 Mg) (View Rituximab (moab C2b8 Anti Cd20, Chimeric) Review and Rituximab (moab C2b8 Anti Cd20, Chimeric) Label ). Patient was hospitalized.

5903099-6 | Tumour Lysis Syndrome
on Sep 24, 2008 Female patient from UNITED STATES , weighting 134.5 lb, was diagnosed with t-cell lymphoma, hypercholesterolaemia, hypertension and was treated with Ontak (View Usage). Patient had the following side effects: tumour lysis syndrome. Ontak dosage: . During the same period patient was treated with VINCRISTINE SULFATE (View Vincristine Sulfate Review and Vincristine Sulfate Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), CYTOXAN (View Cytoxan Review and Cytoxan Label ), PREDNISONE (View Prednisone Review and Prednisone Label ), LIPITOR (View Lipitor Review and Lipitor Label ), LISINOPRIL (View Lisinopril Review and Lisinopril Label ), HYDROCHLOROTHIAZIDE (View Hydrochlorothiazide Review and Hydrochlorothiazide Label ), NEULASTA (View Neulasta Review and Neulasta Label ).

5880051-0 | Ascites, Peritonitis Bacterial, Staphylococcal Infection
on Sep 11, 2008 Female patient from UNITED STATES , weighting 160.9 lb, was treated with Ontak (View Usage). After Ontak was administered, patient had the following side effects: ascites, peritonitis bacterial, staphylococcal infection (What is staphylococcal infection?). Ontak dosage: . During the same period patient was treated with NEXIUM (View Nexium Review and Nexium Label ), SIMVASTATIN (View Simvastatin Review and Simvastatin Label ), MEFORMIN (View Meformin Review and Meformin Label ), GLIPIZIDE (View Glipizide Review and Glipizide Label ), POTASSIUM CHLORIDE (View Potassium Chloride Review and Potassium Chloride Label ), M.V.I. (View M.v.i. Review and M.v.i. Label ), VITAMIN B6 (View Vitamin B6 Review and Vitamin B6 Label ), ASCORBIC ACID (View Ascorbic Acid Review and Ascorbic Acid Label ). Patient was hospitalized.

5723498-5 | Capillary Leak Syndrome, Hyperthyroidism
Patient was taking Ontak (View Usage). Patient experienced the following unwanted or unexpected effects: capillary leak syndrome, hyperthyroidism on Jan 23, 2008 from UNITED STATES Additional patient health information: Female patient , 53 years of age, was diagnosed with mycosis fungoides and. Ontak dosage: 9 Ug/kg, Intravenous. Patient was hospitalized.

5723492-4 | Angiopathy, Chills, Dyspnoea, Pyrexia
Adverse event was reported on Aug 02, 2007 by a Male patient taking Ontak (View Usage) (Dosage: 18 Mcg, 1 In 21 D, Intravenous) was diagnosed with mycosis fungoides and. Location: UNITED STATES , 55 years of age, Patient had the following side effects: angiopathy, chills, dyspnoea, pyrexia. During the same period patient was treated with VINCRISTINE SULFATE (View Vincristine Sulfate Review and Vincristine Sulfate Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), PREDNISONE TAB (View Prednisone Tab Review and Prednisone Tab Label ), CYTOXAN (View Cytoxan Review and Cytoxan Label ), NEULASTA (View Neulasta Review and Neulasta Label ). Patient was hospitalized.

5718724-2 | Disease Progression
on Apr 09, 2008 Male patient from AUSTRALIA , 42 years of age, was diagnosed with mycosis fungoides and was treated with Ontak (View Usage). After Ontak was administered, patient had the following side effects: disease progression. Ontak dosage: 18 Mg, Intravenous Infusion.

5717053-0 | Abdominal Hernia, Arthralgia, Asthenia, Back Pain, Bradycardia, Cardiac Arrest, Cardio-respiratory Arrest, Cardiomegaly, Dyspnoea
on Apr 09, 2008 Female patient from UNITED STATES , 45 years of age, weighting 280.0 lb, was treated with Ontak (View Usage). Patient experienced the following unwanted or unexpected effects: abdominal hernia, arthralgia, asthenia, back pain (What is back pain?), bradycardia, cardiac arrest (What is cardiac arrest?), cardio-respiratory arrest, cardiomegaly, dyspnoea. Ontak dosage: 1620 Mg, 2 In 21 D, Intravenous. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), PREDNISONE TAB (View Prednisone Tab Review and Prednisone Tab Label ), NEULASTA (View Neulasta Review and Neulasta Label ), NORGESTIMATE (NORGESTIMATE) (View Norgestimate (norgestimate) Review and Norgestimate (norgestimate) Label ), ETINOL (View Etinol Review and Etinol Label ), PRILOSEC (View Prilosec Review and Prilosec Label ). Patient was hospitalized.

5710514-X | Arthralgia, Asthenia, Back Pain, Blood Creatine Phosphokinase Increased, Blood Glucose Increased, Cardio-respiratory Arrest, Cardiomegaly, Dyspnoea, Electromechanical Dissociation
Patient was taking Ontak (View Usage). Patient had the following side effects: arthralgia, asthenia, back pain (What is back pain?), blood creatine phosphokinase increased, blood glucose increased, cardio-respiratory arrest, cardiomegaly, dyspnoea, electromechanical dissociation on Mar 31, 2008 from UNITED STATES Additional patient health information: Female patient , 45 years of age, weighting 280.0 lb, . Ontak dosage: 1620 Mg, 2 In 21 D, Intravenous Infusion. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), PREDNISONE TAB (View Prednisone Tab Review and Prednisone Tab Label ), NEULASTA (View Neulasta Review and Neulasta Label ), NORGESTIMATE (NORGESTIMATE) (View Norgestimate (norgestimate) Review and Norgestimate (norgestimate) Label ), ETINOL (View Etinol Review and Etinol Label ), PRILOSEC (View Prilosec Review and Prilosec Label ). Patient was hospitalized.

5694174-2 | Atrial Fibrillation, Blood Amylase Increased, Blood Bicarbonate Decreased, Blood Creatine Phosphokinase Increased, Blood Lactate Dehydrogenase Increased, Capillary Leak Syndrome, Cardiac Arrest, Dizziness
Adverse event was reported on Mar 20, 2008 by a Male patient taking Ontak (View Usage) (Dosage: 1422 Mcg, Intravenous Infusion; Intermitten Since 14 Jan 2008) was diagnosed with lymphoma (What is lymphoma?) and. Location: UNITED STATES , 40 years of age, weighting 180.8 lb, After Ontak was administered, patient had the following side effects: atrial fibrillation (What is atrial fibrillation?), blood amylase increased, blood bicarbonate decreased, blood creatine phosphokinase increased, blood lactate dehydrogenase increased, capillary leak syndrome, cardiac arrest (What is cardiac arrest?), dizziness (What is dizziness?). During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), DOXORUBIENE (DOXORUBICIN HYDROCHLORIDE) (View Doxorubiene (doxorubicin Hydrochloride) Review and Doxorubiene (doxorubicin Hydrochloride) Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), PREDNISONE TAB (View Prednisone Tab Review and Prednisone Tab Label ), NEULASTA (View Neulasta Review and Neulasta Label ). Patient was hospitalized.

5694173-0 | Acidosis, Blood Albumin Decreased, Capillary Leak Syndrome, Cold Sweat, Cyanosis, Dizziness, Hypotension, Hypoxia
on Mar 20, 2008 Male patient from UNITED STATES , 53 years of age, was diagnosed with mycosis fungoides and was treated with Ontak (View Usage). Patient experienced the following unwanted or unexpected effects: acidosis, blood albumin decreased, capillary leak syndrome, cold sweat, cyanosis, dizziness (What is dizziness?), hypotension, hypoxia. Ontak dosage: 18 Mcg, Intravenous Infusion. During the same period patient was treated with DEXAMETHASONE TAB (View Dexamethasone Tab Review and Dexamethasone Tab Label ), SALINE SOLUTION (SALINE MIXTURE) (View Saline Solution (saline Mixture) Review and Saline Solution (saline Mixture) Label ). Patient was hospitalized.

5675840-1 | Arthralgia, Asthenia, Back Pain, Blood Glucose Increased, Cardio-respiratory Arrest, Cardiomegaly, Musculoskeletal Pain, Nausea, Overweight
on Mar 03, 2008 Female patient from UNITED STATES , 45 years of age, weighting 280.0 lb, was treated with Ontak (View Usage). Patient had the following side effects: arthralgia, asthenia, back pain (What is back pain?), blood glucose increased, cardio-respiratory arrest, cardiomegaly, musculoskeletal pain, nausea (What is nausea?), overweight. Ontak dosage: 1620 Mg, 2 In 21 D, Intravenous; Intermittent Since. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), PREDNISONE TAB (View Prednisone Tab Review and Prednisone Tab Label ), NEULASTA (View Neulasta Review and Neulasta Label ), NORGESTIMATE (NORGESTIMATE) (View Norgestimate (norgestimate) Review and Norgestimate (norgestimate) Label ), ETINOL (View Etinol Review and Etinol Label ), PRILOSEC (View Prilosec Review and Prilosec Label ). Patient was hospitalized.

5663756-6 | Atrial Fibrillation, Blood Alkaline Phosphatase Increased, Blood Creatine Phosphokinase Increased, Blood Lactate Dehydrogenase Increased, Cardiac Arrest, Dizziness, Haematocrit Increased, Insomnia
Patient was taking Ontak (View Usage). After Ontak was administered, patient had the following side effects: atrial fibrillation (What is atrial fibrillation?), blood alkaline phosphatase increased, blood creatine phosphokinase increased, blood lactate dehydrogenase increased, cardiac arrest (What is cardiac arrest?), dizziness (What is dizziness?), haematocrit increased, insomnia on Feb 25, 2008 from UNITED STATES Additional patient health information: Male patient , 40 years of age, weighting 180.8 lb, was diagnosed with lymphoma (What is lymphoma?) and. Ontak dosage: 1422 Mcg, Intravenous Infusion. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), DOXORUBIENE (DOXORUBICIN HYDROCHLORIDE) (View Doxorubiene (doxorubicin Hydrochloride) Review and Doxorubiene (doxorubicin Hydrochloride) Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), PREDNISONE TAB (View Prednisone Tab Review and Prednisone Tab Label ), NEULASTA (View Neulasta Review and Neulasta Label ). Patient was hospitalized.

5663755-4 | Asthenia, Bradycardia, Cardio-respiratory Arrest, Cardiomegaly, Dyspnoea, Electromechanical Dissociation, Malaise, Nausea, Pain
Adverse event was reported on Feb 28, 2008 by a Female patient taking Ontak (View Usage) (Dosage: 1620 Mg, 2 In 21 D, Intravenous Infusion) . Location: UNITED STATES , 45 years of age, weighting 280.0 lb, Patient experienced the following unwanted or unexpected effects: asthenia, bradycardia, cardio-respiratory arrest, cardiomegaly, dyspnoea, electromechanical dissociation, malaise, nausea (What is nausea?), pain (What is pain?). During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), PREDNISONE TAB (View Prednisone Tab Review and Prednisone Tab Label ), NEULASTA (View Neulasta Review and Neulasta Label ), NORGESTIMATE (NORGESTIMATE) (View Norgestimate (norgestimate) Review and Norgestimate (norgestimate) Label ), ETINOL (View Etinol Review and Etinol Label ), PRILOSEC (View Prilosec Review and Prilosec Label ). Patient was hospitalized.

5663754-2 | Dyspnoea, Fatigue, Leukopenia, Neutropenia, Thrombocytopenia
on Feb 25, 2008 Male patient from UNITED STATES , 69 years of age, weighting 143.3 lb, was diagnosed with t-cell lymphoma and was treated with Ontak (View Usage). Patient had the following side effects: dyspnoea, fatigue, leukopenia, neutropenia, thrombocytopenia. Ontak dosage: 1206 Mcg, 2 In 21 D, Intravenous Infusion. During the same period patient was treated with CYCLOPHOSPHAMIDE (1357 Mg, 1 In 21 D, Intravenous Infusion) (View Cyclophosphamide Review and Cyclophosphamide Label ), DOXORUBICIN HCL (91 Mg, 1 In 21 D, Intravenous Infusion) (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), PREDNISONE TAB (View Prednisone Tab Review and Prednisone Tab Label ), NEULASTA (View Neulasta Review and Neulasta Label ), PLAVIX (View Plavix Review and Plavix Label ), TOPROL XL (View Toprol-xl Review and Toprol-xl Label ), ASPIRIN TAB (View Aspirin Tab Review and Aspirin Tab Label ).

5643730-6 | Atrial Fibrillation, Blood Alkaline Phosphatase Increased, Blood Lactate Dehydrogenase Increased, Cardiac Arrest, Cardiomegaly, Dizziness, Hepatic Congestion, Insomnia, Oedema
on Feb 11, 2008 Male patient from UNITED STATES , 40 years of age, weighting 180.8 lb, was diagnosed with lymphoma (What is lymphoma?) and was treated with Ontak (View Usage). After Ontak was administered, patient had the following side effects: atrial fibrillation (What is atrial fibrillation?), blood alkaline phosphatase increased, blood lactate dehydrogenase increased, cardiac arrest (What is cardiac arrest?), cardiomegaly, dizziness (What is dizziness?), hepatic congestion, insomnia, oedema. Ontak dosage: 1422 Mcg, Intravenous Infusion. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), DOXORUBIENE (DOXORUBICIN HYDROCHLORIDE) (View Doxorubiene (doxorubicin Hydrochloride) Review and Doxorubiene (doxorubicin Hydrochloride) Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), PREDNISONE TAB (View Prednisone Tab Review and Prednisone Tab Label ), NEULASTA (View Neulasta Review and Neulasta Label ). Patient was hospitalized.

5615037-4 | Blood Alkaline Phosphatase Increased, Blood Lactate Dehydrogenase Increased, Dizziness, Insomnia, Pain, Vomiting
Patient was taking Ontak (View Usage). Patient experienced the following unwanted or unexpected effects: blood alkaline phosphatase increased, blood lactate dehydrogenase increased, dizziness (What is dizziness?), insomnia, pain (What is pain?), vomiting on Jan 18, 2008 from UNITED STATES Additional patient health information: Male patient , 40 years of age, weighting 180.8 lb, was diagnosed with lymphoma (What is lymphoma?) and. Ontak dosage: 1422 Mcg, Intravenous Infusion. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), DOXORUBIENE (DOXORUBICIN HYDROCHLORIDE) (View Doxorubiene (doxorubicin Hydrochloride) Review and Doxorubiene (doxorubicin Hydrochloride) Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), PREDNISONE TAB (View Prednisone Tab Review and Prednisone Tab Label ), NEULASTA (View Neulasta Review and Neulasta Label ). Patient was hospitalized.

5615035-0 | Atrial Fibrillation, Dizziness, Goitre, Hyperthyroidism, Tachycardia, Tremor
Adverse event was reported on Jan 23, 2008 by a Female patient taking Ontak (View Usage) (Dosage: 9 Ug/kg, Intravenous Infusion) was diagnosed with mycosis fungoides and. Location: UNITED STATES , 53 years of age, Patient had the following side effects: atrial fibrillation (What is atrial fibrillation?), dizziness (What is dizziness?), goitre, hyperthyroidism, tachycardia, tremor. Patient was hospitalized.

5615033-7 | Capillary Leak Syndrome, Chest Pain, Hyperthyroidism, Nausea, Palpitations
on Jan 23, 2008 Female patient from UNITED STATES , 53 years of age, was diagnosed with mycosis fungoides and was treated with Ontak (View Usage). After Ontak was administered, patient had the following side effects: capillary leak syndrome, chest pain (What is chest pain?), hyperthyroidism, nausea (What is nausea?), palpitations. Ontak dosage: 18 Ug/kg, Intravenous Infusion. Patient was hospitalized.

5615032-5 | Atrial Fibrillation, Blood Alkaline Phosphatase Increased, Blood Lactate Dehydrogenase Increased, Cardiac Arrest, Dizziness, Insomnia, Pain, Vomiting
on Jan 24, 2008 Male patient from UNITED STATES , 40 years of age, weighting 180.8 lb, was diagnosed with lymphoma (What is lymphoma?) and was treated with Ontak (View Usage). Patient experienced the following unwanted or unexpected effects: atrial fibrillation (What is atrial fibrillation?), blood alkaline phosphatase increased, blood lactate dehydrogenase increased, cardiac arrest (What is cardiac arrest?), dizziness (What is dizziness?), insomnia, pain (What is pain?), vomiting. Ontak dosage: 1422 Mcg, Intravenous Infusion. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), DOXORUBIENE (DOXORUBICIN HYDROCHLORIDE) (View Doxorubiene (doxorubicin Hydrochloride) Review and Doxorubiene (doxorubicin Hydrochloride) Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), PREDNISONE TAB (View Prednisone Tab Review and Prednisone Tab Label ), NEULASTA (View Neulasta Review and Neulasta Label ). Patient was hospitalized.

5599265-2 | Bradycardia, Cardio-respiratory Arrest, Dyspnoea, Fatigue, Musculoskeletal Pain, Sinus Tachycardia, Unresponsive To Stimuli
Patient was taking Ontak (View Usage). Patient had the following side effects: bradycardia, cardio-respiratory arrest, dyspnoea, fatigue, musculoskeletal pain, sinus tachycardia, unresponsive to stimuli on Jan 03, 2008 from UNITED STATES Additional patient health information: Female patient , 45 years of age, weighting 280.0 lb, . Ontak dosage: 1620 Mg, 2 In 21 D, Intravenous. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), PREDNISONE (View Prednisone Review and Prednisone Label ), NEULASTA (View Neulasta Review and Neulasta Label ), NORGESTIMATE (NORGESTIMATE) (View Norgestimate (norgestimate) Review and Norgestimate (norgestimate) Label ), ETINOL (View Etinol Review and Etinol Label ), PRILOSEC (View Prilosec Review and Prilosec Label ). Patient was hospitalized.

5586199-2 | Back Pain, Bradycardia, Cardio-respiratory Arrest, Dyspnoea, Fatigue, Musculoskeletal Pain, Pain In Extremity, Pain In Jaw, Sinus Tachycardia
Adverse event was reported on Dec 24, 2007 by a Female patient taking Ontak (View Usage) (Dosage: 1620 Mg, 2 In 21 D, Intravenous Infusion) . Location: UNITED STATES , 45 years of age, weighting 280.0 lb, After Ontak was administered, patient had the following side effects: back pain (What is back pain?), bradycardia, cardio-respiratory arrest, dyspnoea, fatigue, musculoskeletal pain, pain in extremity, pain in jaw, sinus tachycardia. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), PREDNISONE (View Prednisone Review and Prednisone Label ), NEULASTA (View Neulasta Review and Neulasta Label ). Patient was hospitalized.

5530610-X | Capillary Leak Syndrome, Dizziness, Metabolic Acidosis, Multi-organ Failure, Respiratory Failure, Shock, Syncope, Systemic Inflammatory Response Syndrome
on Nov 28, 2007 Male patient from UNITED STATES , 54 years of age, weighting 213.8 lb, was diagnosed with t-cell lymphoma and was treated with Ontak (View Usage). Patient experienced the following unwanted or unexpected effects: capillary leak syndrome, dizziness (What is dizziness?), metabolic acidosis, multi-organ failure, respiratory failure, shock, syncope, systemic inflammatory response syndrome. Ontak dosage: 18mcg/kg = 1746 Mcg Iv Qd X 4 Days.

5525331-3 | Polymyositis
on Nov 08, 2007 Male patient from UNITED STATES , 48 years of age, was diagnosed with chronic lymphocytic leukaemia and was treated with Ontak (View Usage). Patient had the following side effects: polymyositis. Ontak dosage: 18 Mcg, Intravenous Infusion. During the same period patient was treated with NARCOTICS (View Narcotics Review and Narcotics Label ).

5457776-4 | Febrile Neutropenia
Patient was taking Ontak (View Usage). After Ontak was administered, patient had the following side effects: febrile neutropenia on Sep 05, 2007 from UNITED STATES Additional patient health information: Female patient , 64 years of age, weighting 121.3 lb, was diagnosed with panniculitis and. Ontak dosage: 896 Mcg, Intravenous Infusion. During the same period patient was treated with PREDNISONE TAB (View Prednisone Tab Review and Prednisone Tab Label ), AZATHIOPRINE (View Azathioprine Review and Azathioprine Label ), SYNTHROID (View Synthroid Review and Synthroid Label ), ALLOPURINOL (View Allopurinol Review and Allopurinol Label ), ACYCLOVIR (View Acyclovir Review and Acyclovir Label ). Patient was hospitalized.

5455508-7 | Blood Albumin Decreased, Blood Alkaline Phosphatase Increased, Pyrexia, Rash Maculo-papular
Adverse event was reported on Aug 30, 2007 by a Male patient taking Ontak (View Usage) (Dosage: 9 Ug/kg, Intravenous) was diagnosed with lymphadenopathy, mycosis fungoides and. Location: UNITED STATES , 70 years of age, Patient experienced the following unwanted or unexpected effects: blood albumin decreased, blood alkaline phosphatase increased, pyrexia, rash maculo-papular. During the same period patient was treated with DECADRON (View Decadron Review and Decadron Label ). Patient was hospitalized.

5448922-7 | Acute Myocardial Infarction, Blood Lactic Acid Increased, Bradycardia, Capillary Leak Syndrome, Cardiac Arrest, Electromechanical Dissociation, Haemolysis, Hypotension, Lymphocyte Percentage Decreased
on Aug 22, 2007 Female patient from UNITED STATES , 66 years of age, weighting 134.5 lb, was treated with Ontak (View Usage). Patient had the following side effects: acute myocardial infarction, blood lactic acid increased, bradycardia, capillary leak syndrome, cardiac arrest (What is cardiac arrest?), electromechanical dissociation, haemolysis, hypotension, lymphocyte percentage decreased. Ontak dosage: 1053 Mcg, 2 In 21 D, Intravenous. During the same period patient was treated with VINCRISTINE SULFATE (View Vincristine Sulfate Review and Vincristine Sulfate Label ), DOXORUBIVIN (DOXORUBICIN) (View Doxorubivin (doxorubicin) Review and Doxorubivin (doxorubicin) Label ), CYTOXAN (View Cytoxan Review and Cytoxan Label ), PREDNISONE TAB (View Prednisone Tab Review and Prednisone Tab Label ), LIPITOR (View Lipitor Review and Lipitor Label ), LISINOPRIL (View Lisinopril Review and Lisinopril Label ), HYDROCHLOROTHIAZDE (HYDROCHLOROTHIAZIDE) (View Hydrochlorothiazde (hydrochlorothiazide) Review and Hydrochlorothiazde (hydrochlorothiazide) Label ).

5427734-4 | Bradycardia, Capillary Leak Syndrome, Electromechanical Dissociation, Haemolysis, Hypotension, Myocardial Infarction, Rhabdomyolysis, Tumour Lysis Syndrome, Ventricular Fibrillation
on Aug 14, 2007 Female patient from UNITED STATES , 66 years of age, weighting 134.5 lb, was treated with Ontak (View Usage). After Ontak was administered, patient had the following side effects: bradycardia, capillary leak syndrome, electromechanical dissociation, haemolysis, hypotension, myocardial infarction, rhabdomyolysis, tumour lysis syndrome, ventricular fibrillation. Ontak dosage: 1053 Mcg, Intravenous Infusion. During the same period patient was treated with VINCRISTINE SULFATE (View Vincristine Sulfate Review and Vincristine Sulfate Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), CYTOXAN (View Cytoxan Review and Cytoxan Label ), PREDNISONE TAB (View Prednisone Tab Review and Prednisone Tab Label ), LIPITOR (View Lipitor Review and Lipitor Label ), LISINOPRIL (View Lisinopril Review and Lisinopril Label ), HYDROCHLOROTHIAZIDE (View Hydrochlorothiazide Review and Hydrochlorothiazide Label ).

5418039-6 | Rhabdomyolysis
Patient was taking Ontak (View Usage). Patient experienced the following unwanted or unexpected effects: rhabdomyolysis on Aug 06, 2007 from UNITED STATES Additional patient health information: Female patient , 66 years of age, weighting 134.5 lb, was diagnosed with hypertension and. Ontak dosage: 1053 Mcg Intravenous Infusion Intermittent Since 30 Jul 2007 - 07/31/2007. During the same period patient was treated with VINCRISTINE SULFATE (View Vincristine Sulfate Review and Vincristine Sulfate Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), CYTOXAN (View Cytoxan Review and Cytoxan Label ), PREDNISONE TAB (View Prednisone Tab Review and Prednisone Tab Label ), LIPITOR (View Lipitor Review and Lipitor Label ), LISINOPRIL (View Lisinopril Review and Lisinopril Label ), HYDROCHLOROTHIAZIDE (View Hydrochlorothiazide Review and Hydrochlorothiazide Label ).

5417991-2 | Rhabdomyolysis
Adverse event was reported on Aug 06, 2007 by a Female patient taking Ontak (View Usage) (Dosage: 1053 Mcg Intermittent Since 30 Jul 2007 - 07/31/2007) was diagnosed with hypertension and. Location: UNITED STATES , 66 years of age, weighting 134.5 lb, Patient had the following side effects: rhabdomyolysis. During the same period patient was treated with VINCRISTINE SULFATE (View Vincristine Sulfate Review and Vincristine Sulfate Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), CYTOXAN (View Cytoxan Review and Cytoxan Label ), PREDNISONE TAB (View Prednisone Tab Review and Prednisone Tab Label ), LIPITOR (View Lipitor Review and Lipitor Label ), LISINOPRIL (View Lisinopril Review and Lisinopril Label ), HYDROCHLOROTHIAZIDE (View Hydrochlorothiazide Review and Hydrochlorothiazide Label ).

5320951-3 |
on Apr 23, 2007 Male patient from UNITED STATES , 53 years of age, was diagnosed with lymphoma (What is lymphoma?) and was treated with Ontak (View Usage). . Ontak dosage: 18 Ug/kg/d Daily Iv.

5165877-3 | Toxic Epidermal Necrolysis
on Nov 13, 2006 Female patient from UNITED STATES , 42 years of age, was diagnosed with mycosis fungoides and was treated with Ontak (View Usage). Patient experienced the following unwanted or unexpected effects: toxic epidermal necrolysis. Ontak dosage: . Patient was hospitalized.

5130885-5 | Capillary Leak Syndrome, Hypoalbuminaemia, Malaise, Oliguria, Pleural Effusion, Red Blood Cell Schistocytes Present, Renal Failure Acute, Thrombotic Thrombocytopenic Purpura
Patient was taking Ontak (View Usage). Patient had the following side effects: capillary leak syndrome, hypoalbuminaemia, malaise, oliguria, pleural effusion, red blood cell schistocytes present, renal failure acute, thrombotic thrombocytopenic purpura on Aug 01, 2006 from UNITED STATES Additional patient health information: Male patient , 77 years of age, was diagnosed with mycosis fungoides and. Ontak dosage: . During the same period patient was treated with ATORVASTATIN CALCIUM (View Atorvastatin Calcium Review and Atorvastatin Calcium Label ), BEXAROTENE (View Bexarotene Review and Bexarotene Label ), DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), DOXAZOSIN MESYLATE (View Doxazosin Mesylate Review and Doxazosin Mesylate Label ), FUROSEMIDE (View Furosemide Review and Furosemide Label ), LEVOFLOXACIN (View Levofloxacin Review and Levofloxacin Label ), LEVOTHYROXINE SODIUM (View Levothyroxine Sodium Review and Levothyroxine Sodium Label ), LISINOPRIL (View Lisinopril Review and Lisinopril Label ). Patient was hospitalized.

5115390-4 | Peritoneal Haemorrhage, Respiratory Distress, Splenic Rupture, Syncope, Thrombophlebitis
Adverse event was reported on Sep 07, 2006 by a Male patient taking Ontak (View Usage) (Dosage: 18 Ug/kg/d Qd Iv) was diagnosed with mycosis fungoides and. Location: AUSTRALIA , 57 years of age, weighting 133.2 lb, After Ontak was administered, patient had the following side effects: peritoneal haemorrhage, respiratory distress, splenic rupture, syncope, thrombophlebitis. During the same period patient was treated with ASPIRIN (View Aspirin Review and Aspirin Label ), AMLODIPINE (View Amlodipine Review and Amlodipine Label ), ATORVASTATIN (View Atorvastatin Review and Atorvastatin Label ), BETAMETHASONE (View Betamethasone Review and Betamethasone Label ), ISOSORBIDE MONONITRATE (View Isosorbide Mononitrate Review and Isosorbide Mononitrate Label ), TENORMIN (View Tenormin Review and Tenormin Label ). Patient was hospitalized.

5008577-2 | Pyrexia
on May 22, 2006 Male patient from UNITED STATES , 44 years of age, weighting 172.0 lb, was diagnosed with t-cell lymphoma and was treated with Ontak (View Usage). Patient experienced the following unwanted or unexpected effects: pyrexia. Ontak dosage: 18 Mcg/kg Days 1+2 Ea Cycle Iv Drip. During the same period patient was treated with CYCLOPHOSPHAMIDE (Days 3 Ea Cycle Iv Drip) (View Cyclophosphamide Review and Cyclophosphamide Label ), DOXORUBICIN VIN 1.4 MG/M2 (View Doxorubicin-vin 1.4 Mg/m2 Review and Doxorubicin-vin 1.4 Mg/m2 Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ). Patient was hospitalized.

4981685-8 | Blood Creatinine Increased, Haematoma, Syncope
on Apr 20, 2006 Male patient from UNITED STATES , weighting 220.0 lb, was diagnosed with neoplasm and was treated with Ontak (View Usage). Patient had the following side effects: blood creatinine increased, haematoma, syncope. Ontak dosage: 1778 Mcg. Patient was hospitalized.

4932999-9 | Autoimmune Disorder, Cataract Nuclear, Corneal Disorder, Disease Recurrence, Lymphoma, Maculopathy
Patient was taking Ontak (View Usage). After Ontak was administered, patient had the following side effects: autoimmune disorder, cataract nuclear, corneal disorder, disease recurrence, lymphoma (What is lymphoma?), maculopathy on Feb 14, 2006 from UNITED STATES Additional patient health information: Female patient , 63 years of age, weighting 114.4 lb, was diagnosed with b-cell lymphoma and. Ontak dosage: 18 Ug/kg/d Qd Iv. During the same period patient was treated with ACETAMINOPHEN (View Acetaminophen Review and Acetaminophen Label ), DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), DIPHENHYDRAMINE (View Diphenhydramine Review and Diphenhydramine Label ), FERROUS SULFATE TAB (View Ferrous Sulfate Tab Review and Ferrous Sulfate Tab Label ), FUROSEMIDE (View Furosemide Review and Furosemide Label ), INTRAVENOUS SALINE (View Intravenous Saline Review and Intravenous Saline Label ), LORAZEPAM (View Lorazepam Review and Lorazepam Label ).

4932812-X | Blood Pressure Immeasurable, Bradycardia, Erythema, Eye Rolling, Feeling Abnormal, Infusion Related Reaction, Loss Of Consciousness, Miosis, Moaning
Adverse event was reported on Mar 02, 2006 by a Male patient taking Ontak (View Usage) (Dosage: 855 Mg Q D X 5d Q 3 Weeks Iv) was diagnosed with t-cell lymphoma and. Location: UNITED STATES , 70 years of age, weighting 212.0 lb, Patient experienced the following unwanted or unexpected effects: blood pressure immeasurable, bradycardia, erythema, eye rolling, feeling abnormal, infusion related reaction, loss of consciousness, miosis, moaning. During the same period patient was treated with TYLENOL (CAPLET) (View Tylenol (caplet) Review and Tylenol (caplet) Label ), DECADRON SRC (View Decadron Src Review and Decadron Src Label ), ZOFRAN (View Zofran Review and Zofran Label ), CENTRUM SILVER (View Centrum Silver Review and Centrum Silver Label ), CIPRO (View Cipro Review and Cipro Label ), SINGULAIR (View Singulair Review and Singulair Label ).

4838492-6 | Erythema Multiforme, Graft Versus Host Disease, Multi-organ Failure, Oedema, Purpura, Rash Pruritic, Staphylococcal Infection, Thrombocytopenia, Toxic Epidermal Necrolysis
on Nov 08, 2005 Male patient from UNITED STATES , 45 years of age, was diagnosed with follicle centre lymphoma, follicular grade i, ii, iii and was treated with Ontak (View Usage). Patient had the following side effects: erythema multiforme, graft versus host disease, multi-organ failure, oedema, purpura, rash pruritic, staphylococcal infection (What is staphylococcal infection?), thrombocytopenia, toxic epidermal necrolysis. Ontak dosage: 18 Ug/kg/d Once Iv. During the same period patient was treated with DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), HYDROMORPHONE HYDROCHLORIDE (View Hydromorphone Hydrochloride Review and Hydromorphone Hydrochloride Label ), HYDROXYZINE HYDROCHLORIDE (View Hydroxyzine Hydrochloride Review and Hydroxyzine Hydrochloride Label ), PANTOPRAZOLE (View Pantoprazole Review and Pantoprazole Label ), PIPERACILLIN SODIUM/TAZOBACTAM SODIUM (View Piperacillin Sodium/tazobactam Sodium Review and Piperacillin Sodium/tazobactam Sodium Label ), SILVER SULFADIAZINE (View Silver Sulfadiazine Review and Silver Sulfadiazine Label ), ZOLPIDEM TARTRATE (View Zolpidem Tartrate Review and Zolpidem Tartrate Label ). Patient was hospitalized.

4835161-3 | Blood Calcium Increased, Depressed Level Of Consciousness, Fatigue, Hepatomegaly, Lymphoma, Malignant Neoplasm Progression, Rash, White Blood Cell Count Increased
on Oct 26, 2005 Female patient from UNITED STATES , 42 years of age, was diagnosed with adult t-cell lymphoma/leukaemia and was treated with Ontak (View Usage). After Ontak was administered, patient had the following side effects: blood calcium increased, depressed level of consciousness, fatigue, hepatomegaly, lymphoma (What is lymphoma?), malignant neoplasm progression, rash (What is rash?), white blood cell count increased. Ontak dosage: 150 Mcg Daily Iv. Patient was hospitalized.

4757925-7 | Paraneoplastic Syndrome, Retinopathy, Visual Acuity Reduced
Patient was taking Ontak (View Usage). Patient experienced the following unwanted or unexpected effects: paraneoplastic syndrome, retinopathy, visual acuity reduced on Aug 11, 2005 from UNITED STATES Additional patient health information: Male patient , 75 years of age, weighting 176.4 lb, was diagnosed with b-cell small lymphocytic lymphoma, chronic lymphocytic leukaemia and. Ontak dosage: 18 Ug/kg/d Qd Iv. During the same period patient was treated with LEVOTHYROXINE SODIUM (View Levothyroxine Sodium Review and Levothyroxine Sodium Label ), LISINOPRIL (View Lisinopril Review and Lisinopril Label ), LORATADINE (View Loratadine Review and Loratadine Label ), PHENTERMINE (View Phentermine Review and Phentermine Label ).

4757728-3 | Angiopathy, Cardiac Tamponade, Hypogammaglobulinaemia, Lymphadenopathy, Optic Disc Disorder, Papilloedema, Pericardial Effusion, Polycythaemia, Visual Acuity Reduced
Adverse event was reported on Jul 27, 2005 by a Female patient taking Ontak (View Usage) (Dosage: ) was diagnosed with chronic lymphocytic leukaemia and. Location: AUSTRALIA , 54 years of age, Patient had the following side effects: angiopathy, cardiac tamponade, hypogammaglobulinaemia, lymphadenopathy, optic disc disorder, papilloedema, pericardial effusion, polycythaemia, visual acuity reduced.

4751189-6 | Adenocarcinoma, Csf Lactate Dehydrogenase Increased, Csf Protein Increased, Disease Progression, Metastases To Lung, Metastasis, Retinopathy
on Apr 26, 2004 Male patient from AUSTRALIA , 65 years of age, was diagnosed with chronic lymphocytic leukaemia and was treated with Ontak (View Usage). After Ontak was administered, patient had the following side effects: adenocarcinoma, csf lactate dehydrogenase increased, csf protein increased, disease progression, metastases to lung, metastasis, retinopathy. Ontak dosage: . During the same period patient was treated with IMMUNE GLOBULIN INTRAVENOUS (HUMAN) (View Immune Globulin Intravenous (human) Review and Immune Globulin Intravenous (human) Label ), METOCLOPRAMIDE HYDROCHLORIDE (View Metoclopramide Hydrochloride Review and Metoclopramide Hydrochloride Label ), OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ), TRIMETHOPRIM SULFAMETHOXAZOLE (View Trimethoprim-sulfamethoxazole Review and Trimethoprim-sulfamethoxazole Label ).

4727115-2 | Abasia, Aseptic Necrosis Bone, Condition Aggravated, Mycosis Fungoides
on Jul 11, 2005 Female patient from UNITED STATES , 30 years of age, was diagnosed with mycosis fungoides and was treated with Ontak (View Usage). Patient experienced the following unwanted or unexpected effects: abasia, aseptic necrosis bone, condition aggravated, mycosis fungoides. Ontak dosage: 15 Ug/kg/d Qd Iv. During the same period patient was treated with TARGRETIN (525 Mg Qd Po) (View Targretin Review and Targretin Label ), VALACYCLOVIR HCL (View Valacyclovir Hcl Review and Valacyclovir Hcl Label ).

4725173-2 | Cataract Nuclear, Impaired Driving Ability, Macular Scar, Maculopathy, Retinitis, Retinopathy Hypertensive
Patient was taking Ontak (View Usage). Patient had the following side effects: cataract nuclear, impaired driving ability, macular scar, maculopathy, retinitis, retinopathy hypertensive on Jul 08, 2005 from UNITED STATES Additional patient health information: Female patient , 63 years of age, weighting 114.4 lb, was diagnosed with b-cell lymphoma and. Ontak dosage: 18 Ug;kg/d Qd Iv. During the same period patient was treated with ACETAMINOPHEN (View Acetaminophen Review and Acetaminophen Label ), DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), DIPHENHYDRAMINE HCL (View Diphenhydramine Hcl Review and Diphenhydramine Hcl Label ), FERROUS SULFATE TAB (View Ferrous Sulfate Tab Review and Ferrous Sulfate Tab Label ), FUROSEMIDE (View Furosemide Review and Furosemide Label ), INTRAVENOUS SALINE (View Intravenous Saline Review and Intravenous Saline Label ), LORAZEPAM (View Lorazepam Review and Lorazepam Label ).